In the last decade, significant improvements in the prognosis of patients with HER2-positive breast cancer have been achieved using HER2-targeted therapies. However, despite encouraging results, the majority of patients develop acquired resistance due to extensive cross-talk and feedback loops associated with alternate HER family members and downstream MAPK-PI3K/Akt/mTOR pathways.
2

Translational Relevance
In the last decade, significant improvements in the prognosis of patients with HER2-positive breast cancer have been achieved using HER2-targeted therapies. However, despite encouraging results, the majority of patients develop acquired resistance due to extensive cross-talk and feedback loops associated with alternate HER family members and downstream MAPK-PI3K/Akt/mTOR pathways.
Our current study demonstrates in vivo and in vitro proof-of-concept that an antibody against the ectodomain of E-cadherin (DECMA-1) selectively induces apoptosis and reduces tumor growth by down-regulating all HER family members, and components of the MAPK-PI3K/Akt/mTOR and IAP pathways, thereby successfully overcoming multiple resistance pathways. More importantly, we show that this occurs without any detectable cytotoxicity to mice, end-organs or a panel of normal human epithelial or mesenchymal cells in culture. These findings provide a rationale for the development and 
Introduction
Breast cancer, a heterogeneous disease with multiple subgroups and molecular signatures, remains the second leading cause of cancer-related deaths in women (1) . One of the most successful strategies in the treatment of breast cancers involves the administration of monoclonal antibodies directed against epitopes of the human epidermal growth factor receptor family (HER) that are abundant on tumor cells. In this regard, Trastuzumab (Herceptin®), a humanized mAb against the extracellular domain of HER2 has revolutionized the care of HER2-positive cancers, an aggressive subtype representing 20-25% of breast cancers (1) . However, despite encouraging clinical trials, targeted mAb therapies for HER2 positive breast cancers have only had a modest efficacy due to the development of cancer cell resistance (1, 2) .
Several key cell survival pathways have been suggested to contribute to cancer cell resistance, including signaling by other HER family members (HER1, 3, 4) , hyperactivation of the PI3K (phosphatidylinositol 3-kinase)/Akt and MEK/ERK (mitogen-activated protein kinase) signaling axis and dysregulation of the inhibitor of apoptosis (IAPs) proteins (1, 2) . It is well documented that Trastuzumab efficiently blocks HER2-HER2 homodimer signaling, but has little effect on HER1, HER3 or HER4 homodimers or heterodimers (1, 2) . Along these lines, the TtzmR BT474 cell line exhibited higher levels of endogenous phospho-HER1 and HER1/HER2 heterodimers, the latter of which was not inhibited by Trastuzumab treatment (3) . This is consistent with clinical reports, in which patients with HER2-overexpressing tumors that became resistant to Trastuzumab responded to the HER1/HER2 inhibitors Lapatinib and HKI-272 (4, 5) . HER3 contains six PI3K binding sites, which make the HER2/HER3 heterodimers among the most potent activators of the PI3K-Akt pathway (6) .
Studies have shown that sustained MAPK and PI3K/Akt signaling is integral to Trastuzumab-induced resistance (7) . Notably, constitutive PI3K/Akt signaling prevented cell-cycle arrest and apoptosis mediated by Trastuzumab, and BT474 TtzmR clones demonstrated enhanced phospho-Akt and Akt kinase activity (8, 9) . Not surprisingly, preclinical studies in HER2-amplified cell lines and xenograft models demonstrated that the bispecific mAb Pertuzumab, which blocks ligand-induced HER2/HER3 dimerization, effectively disrupted HER2-HER3 heterodimers, leading to inhibition of downstream MAPK and PI3K signaling and significant anti-tumor activity (9) . Combination therapy with Trastuzumab and Pertuzumab also exhibited enhanced anti-tumor activity in models of Trastuzumab resistance, suggesting that both drugs have complimentary mechanisms of action (10) . Interactions of the HER family, with other major gene families regulating cell survival, such as the inhibitor of apoptosis proteins (IAPs) also confer resistance to apoptosis in breast cancer cells (11, 12) .
Constitutive overexpression of survivin, the smallest IAP family member downstream of PI3K, was shown to be indispensable for survival of HER2-positive breast cancer cells that exhibited intrinsic cross-resistance to multiple HER1/2 inhibitors (13). Moreover, co-expression of HER1 and HER2 enhanced survivin levels, resulting in enhanced resistance to etoposide-induced apoptosis (11) .
Therefore, it is clear that HER2-positive cancers may benefit from therapeutic approaches that simultaneously block multiple HER receptor family members.
Prior studies have shown a clear interaction between the HER receptor family and E-cadherin, a transmembrane protein that mediates calcium-dependent homophilic cell-cell adhesions. HER1 (EGFR) activation was shown to disrupt adherens junctions and chronic HER1 stimulation enhanced the E-cadherin transcriptional repressors, TWIST and Snail (14, 15) . Conversely, in lung and breast cancer cell lines, inhibition of HER1 signaling increased intact E-cadherin and restored adherens junctions (16, 17) , suggesting an inverse correlation between E-cadherin and HER family members.
Recent studies in our laboratory, as well as others, also demonstrate a direct interaction between the shed E-cadherin ectodomain fragment, sEcad, and the HER receptors (18, 19) . sEcad is derived from the proteolytic cleavage of the extracellular domain of E-cadherin, which contains five subdomains, termed EC1-5 (20) . This ectodomain shedding, mediated by metalloproteinases (MMPs) or members of the ADAMs (a disintegrin and metalloproteinases), leads to the release of an 80 kDa sEcad fragment into the extracellular space (21) . sEcad is constitutively shed at low levels in normal
Research. 6 epithelial cells, but is significantly elevated in breast cancer patients and correlates with tumor size, clinical response to chemotherapy and predicts a shorter disease-free interval (22) . In prostate, skin and ovarian cancer cells, addition of a purified 80kDa sEcad fragment or recombinant sEcad chimeric protein (rhEcad/Fc) destabilized adherens junctions, enhanced tumor cell proliferation, migration and invasion (18, 19, 21, 23, 24) . This sEcad induced invasion was shown to be MMP-2, MMP-9 and/or MT1-MMP dependent in lung and skin cancer cells (18, 25) . Although the mechanisms for these prooncogenic effects have yet to be elucidated, we recently demonstrated endogenous and exogenous sEcad binding to HER1, HER2 and the insulin-like growth factor-1receptor (IGF-1R) in human skin squamous cell cancer specimens and skin cancer cells (18) . Similarly, Najy et al (2008) demonstrated endogenous sEcad binding to HER2 and HER3 in E-cadherin-positive MCF-7 breast cancer cells, and exogenous sEcad associating with HER2 in E-cadherin-negative SKBR3 cells (19) . The latter resulted in HER2-HER3 heterodimerization, HER3 phosphorylation and ERK activation. Consistent with these results, exogenous sEcad promoted cell survival and acted as a potent anti-apoptotic protein, via HER1, Akt and ERK signaling in serum starved transformed Madin-Darby canine kidney (MDCK) cells and in polarized epithelial acini (26) . Furthermore, exogenous sEcad induced the phosphorylation of HER1, HER2 and IGF-1R in PAM212 and CC4A skin cancer cells, and depending on the cell-type, resulted in the activation of downstream MAPK-PI3K/Akt/mTOR signaling (18) . Therefore, although an inverse relationship exists between intact E-cadherin and HERs, it is clear that the shed ectodomain sEcad fragment binds to HER family members and nurtures the growth and survival of various cancers, demonstrating a potential important role of targeting sEcad and sEcad-HER receptor interactions in breast carcinogenesis.
In this study, we set out to explore whether a commercially available monoclonal antibody (DECMA-1) that specifically targets epitopes within the extracellular domain of E-cadherin, is able to suppress breast carcinogenesis in vivo and in vitro. We show that DECMA-1 mAb treatment exhibits potent anticancer activity and effectively downregulates HER1-4 family members and multiple
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Cells and reagents
Human MCF-7, BT474-parental, MCF-10A, primary epidermal keratinocytes (PHK), and primary epidermal melanocytes (Mel) were purchased from ATCC, and cultured according to ATCC recommendations. Trastuzumab-resistant BT474 (TtzmR) cells were generously provided by Dr. Kute 
Immunoprecipitation, subcellular fractionation and western blotting
Protein extraction in cells was performed on ice using total protein extraction buffer: 20mM Tris pH7.5, 137mM NaCl, 100mM NaF, 10% glycerol, 1% NP40, 1mM PMSF and protease inhibitor cocktail (Sigma). Protein concentration was measured using a BCA Protein Assay Kit (Pierce). Protein samples (10-100ȝg) were denatured at 95°C (unless otherwise stated) and subsequently separated by 4-15% SDS-PAGE gel electrophoresis. After transfer to nitrocellulose membrane and blocking with 5% nonfat milk, samples were probed with primary antibodies. Western Blot images were captured using HP Scanjet G4050 and analyzed relative to G3PDH or actin using NIH Scion Image. Subcellular fractionation was performed using the BioVision FractionPREP Cell Fractionation System (BioVision Inc), as per the manufacturer's instructions. IAP family members, in the presence or absence of DECMA-1, were analyzed using a Human Apoptosis Array kit (R&D Systems). Immunoprecipitation assays were carried out by harvesting cells with immunoprecipitation lysis buffer (20 mM Tris-HCl, pH 7.5; 137 mM NaCl; 100 mM NaF; 10% glycerol; 1 % Nonidet P-40; 1mM PMSF and protease inhibitor cocktail) (Sigma). After brief sonication, lysates were cleared by centrifugation at 4 °C. Supernatants DECMA-1 (U5885, Sigma), as previously described (18, 27) .
Histological analysis and immunohistochemistry
Paraffin-embedded tumors were fixed, sectioned at 5μm, deparaffinized and stained with H&E according to standard protocols. H&E-stained slides were evaluated by a board-certified pathologist (C. Tornos). For immunohistochemical analyses, tissues were stained using anti-HER1, HER2, HER3
Research. 11 HER4, p53, ERK1/2, Akt, mTOR and survivin (Cell Signaling) antibodies, as previously described (18, 27) .
Statistical Analysis
Comparisons between groups were made using ANOVA followed by post-hoc analysis using the Student-Newman-Keuls or Dunnett's method unless otherwise stated. Statistical significance is indicated in figures as *P < 0.05, **P<0.01 or ***P<0.001.
Study approval
This study was conducted in accordance with NIH guidelines for the use of experimental animals. Fig.1 A-B) . In these tumors that developed, pathological analysis by H&E staining of histologic sections revealed that control, IgG and mAb treated tumors were poorly differentiated (tumor grade of 3, architectural grade of 3, and nuclear grade of 3), except in one of five DECMA-1 treated mice in which the tumor was moderately differentiated (tumor grade 2, architectural grade 2, nuclear grade 1) (Fig. 1B) .
Immunohistochemical analyses of these tumors were then performed, so as to determine the potential mechanisms for the decreased tumorigenesis after DECMA-1 mAb therapy. Consistent with decreased tumor burden, there was a statistically significant decrease in BrdU staining in mAb treated tumors versus controls (Fig. 1C) . In contrast, apoptosis was significantly increased in tumors from mice treated with DECMA-1 mAb compared with all control groups as measured by TUNEL analyses (Fig. 1D) . Taken together, these data show that targeted mAb therapy against the membrane proximal region of the ectodomain of E-cadherin significantly delayed tumor growth and tumor burden by reducing proliferation, but more importantly by inducing tumor cell death. Fig. 2A) and cellular proliferation (Fig. 2B) compared to control groups. Blebbing of the cellular membrane began to appear after incubation with the mAb for 24-48 h and resulted in ~70% loss of attached cells (Fig. 2C) , suggesting induction of programmed cell death and/or necrosis. ELISA quantification of histone-associated DNA fragments confirmed the phase contrast images and demonstrated a significant DECMA-1 mAb-mediated induction of apoptosis 48 h following treatment (Fig. 2D ), but no effects on necrosis (data not shown). As p53 activation is important in the induction of apoptosis, we next investigated whether the effects of DECMA-1 treatment involved p53. The intensity of p53 immunohistochemical staining and western blotting in tumors from DECMA-1 treated MMTV-PyMT mice was dramatically increased compared to saline or IgG treated mice (Fig 3A) . Interestingly, DECMA-1 also remarkably increased p53 expression in MCF-7 cells as demonstrated by immunoblotting and immunofluorescence staining ( Fig. 3B and C) , whereas it decreased the mutant p53 expression in BT474 TtzmR cells (Fig. 3B) . Since one potential mechanism for these DECMA-1-induced effects appeared to be through alteration of p53 expression, we next determined the effect of DECMA-1 on apoptosis in both wild-type p53 (MCF-7) and mutant p53 (parental BT474) cell lines. Our results show that DECMA-1 treatment significantly increased apoptosis, regardless of p53 mutation status (Fig. 3D) .
Research. (Fig. 4B) . Moreover, in DECMA-1-treated mice, resected tumors exhibited a decrease in ERK1/2, Akt and mTOR immunostaining and a decrease in the expression levels of pMEK1/2, pPI3K and p4E-BP1,but not p70S6K (Fig. 4C and D) . As HER receptor signaling involves IAP family members (11, 12) , we next evaluated the expression level of the IAP family member survivin in the resected tumors by immunohistochemistry and western blotting. In saline and IgG treated mice, survivin immunostaining was predominately nuclear whereas in DECMA-1 treated mice a clear reduction in survivin immunoreactivity was noted (Fig. 4C) and subsequently confirmed by immunoblotting (Fig. 4D) . Consistent with the in vivo findings, immunoblotting of membrane fractions of DECMA-1 treated MCF-7 cells revealed a marked reduction in HER1-4, pERK1/2, pAkt, pRaptor, pmTOR and its substrate p4E-BP1, while pp70S6K and pPI3K levels remained essentially unchanged (Fig. 4E) . Moreover, analysis of IAP family members using a Human Apoptosis Array kit demonstrated decreased expression levels of several IAPs, including XIAP, survivin and c-IAP-1 following DECMA-1 treatment (Fig. 4F) . Altogether, these data show that a 
Degradation of HER receptors by ectodomain-specific E-cadherin mAb DECMA-1
As endocytic trafficking and ubiquitin-mediated degradation of cell surface receptors potentially provides an important mechanism of HER receptor regulation (29), we next assessed whether DECMA-1 decreased HER expression levels by inducing their internalization and degradation. HER1-4 receptor immunofluorescence in control MCF-7 cells demonstrated predominantly plasma membrane localization, whereas mAb treatment induced HER receptor down-regulation and aggregation into intracellular vesicular structures (Fig. 5A ). In addition, using equal IP products for HER1 and HER2 (minimal protein was recovered from DECMA-1 treated cells), ubiquitination was dramatically increased in the cytosol and membrane fractions of treated cells (Fig. 5B) . Subsequent experiments showed that DECMA-1treatment induced tumor cell apoptosis by mediating HER receptor degradation. Chloroquine, a lysosomal inhibitor, prevented DECMA-1-induced apoptosis at low doses and rescued HER1-4 receptor membrane expression (Fig. 5C-D) . In addition, the effect of DECMA-1 on apoptosis was inhibited in the presence of the proteasome inhibitor ALLN and was accompanied by the rescue of membrane HER1-4 expression (Fig. 5C-D) . Thus, the lysosome and ubiquitin-proteasome pathways play an important role in the ectodomain-specific E-cadherin mAbinduced HER receptor degradation and apoptosis in E-cadherin/HER2-positive breast cancer cells.
DECMA-1 binds to human and mouse mammary tumors but does not exert toxicity to normal tissues and cells
Because skin toxicity is a common drug-related adverse event observed in cancer patients treated with HER-directed monoclonal antibody therapies (30), we next evaluated the binding specificity of different EC-domain-specific antibodies to intact E-cadherin or the shed E-cadherin ectodomain, on normal human skin specimens lysed in PBS under non-reduced and reduced conditions by western blotting. In normal human skin tissues, lysed in PBS under either reduced or non-reduced conditions, DECMA-1 predominately bound to sEcad with minimal binding to FL-Ecad (Fig. 6A) . In contrast, an antibody against the C-terminal region of E-cadherin mainly recognized FL-Ecad, whereas SHE78-7 and HECD-1 which were generated against EC1 and EC2, respectively, bound both FL-Ecad and sEcad by immunoblotting (Fig. 6A) . To determine whether DECMA-1 binds intact E-cadherin and/or the shed soluble ~80 kDa ectodomain fragment in tumors, we next evaluated binding levels of DECMA-1 in human and mouse breast cancer specimens lysed in PBS by immunoblotting. In both human and mouse specimens, DECMA-1 bound both intact E-cadherin (120 kDa) and the soluble shed fragment (80kDa), albeit at much higher levels in the latter (Fig. 6B and C) . Furthermore, immunofluorescence microscopy of Triton-X-treated tissue sections demonstrated both membrane and cytosolic staining for DECMA-1, confirming the immunoblot results ( Fig. 6B and C 
). In our in vitro studies, TUNEL analyses in both normal human breast cells (MCF-10A) and cancer cells (MCF-7)
demonstrated an increase in apoptosis in breast cancer cells, but no change of cell death in normal mammary cells (Fig. 6D) . Moreover, DECMA-1 treatment of confluent human normal mammary epithelial cells (E-cadherin-positive; MCF-10A; Mam), fibroblasts (E-cadherin-negative; Fib), primary human epidermal keratinocytes (E-cadherin-positive; PHK) and melanocytes (E-cadherin-positive; Mel) also exhibited no significant induction of apoptosis compared with IgG controls as assessed by a Cell Death ELISA Assay (Fig. 6E) . Because rapidly dividing cells of the intestine have been shown to be significantly impacted in conditional E-cadherin knock-out models, and gastrointestinal side effects are common with HER-targeted therapies (31, 32), we next verified that the intestinal architecture is not altered upon prolonged DECMA-1 treatment. In accordance with these in vitro findings, DECMA-1 treated MMTV-PyMT mice exhibited no overt signs of toxicity (i.e. grooming, vocalization, hunched posture, or change in appetite or body weight) and no cytotoxicity was observed in excised intestine (Fig. 6F ) or in heart, liver, lung and kidney sections by H&E analysis (Data not shown). Collectively, these data show that DECMA-1 binds predominately the ~80kDa ectodomain of E-cadherin in human (35) , and acts in a paracrine or autocrine manner to stimulate tumor cell growth and survival (18, 26) . Accordingly, levels of sEcad in breast cancer patients correlates with tumor size, response to chemotherapy and predicts a shorter disease-free interval (22) . Reports further show elevated sEcad expression levels in primary gastric and prostate tumors, skin cancers and metastatic foci (18, 36, 37) . This distinct pro-oncogenic property of sEcad is further supported by studies in ovarian, skin, prostate and transformed MDCK cancer cell lines, whereby recombinant sEcad disrupted E-cadherin-mediated cell-cell adhesions and enhanced migration and invasion, whereas immunodepletion of sEcad from the conditioned media reversed these effects (18, 21, 23, 24) . Although the mechanisms of action of sEcad are not well understood, both HER2 overexpression and enhanced sEcad predict for a poor clinical outcome in breast cancer, making it tempting to
Research. speculate that the two interact. Along these lines, we and others have demonstrated that sEcad binds to HER family members to increase tumor growth and cell survival (18, 26) . Specifically, we have shown that endogenous and exogenous sEcad binds to HER1, HER2 and IGF-1R in human skin SCC specimens and mouse SCC cell lines (18) . Similarly, Najy and colleagues (2008) 
by SHE78-7 was further documented in LNCaP prostate and SUM185 breast cancer cells (42) and intraperitoneal administration of SHE78-8 was shown to significantly prolong survival and prevent peritoneal bleeding (indicative of advanced disease) compared to controls in an HT29 colorectal xenograft model (43) . Lastly, Tomlinson et al (2001) demonstrated that 5 day injections of HECD-1 (EC2 domain monoclonal antibody) resulted in a decrease in both the size and number of pulmonary lymphovascular emboli using a MARY-X human inflammatory breast carcinoma xenograft model (44) .
Because the tumor suppressor p53 is well known to activate apoptosis, and disruption of this process can promote tumor progression and chemoresistance, we next sought to determine if these DECMA-1-induced effects were p53 mediated. Interestingly, in MMTV-PyMT tumors and HER2-positive MCF-7 cells (wild-type p53), DECMA-1 treatment significantly increased wild type p53 expression, but in BT474 TtzmR cells decreased mutant p53 levels. Importantly, one of the gain-offunction effects of mutant p53 is apoptotic resistance to pro-apoptotic stimuli, including growth factors deprivation, Ȗ-irradiation and anticancer agents (45) . Accordingly, Mirzayans et al (2012) demonstrated that siRNA-mediated knockdown of mutant p53 in BT474 cells significantly increased cell death via apoptosis (46) , which is consistent with our findings. Taken together, alteration of p53 expression is likely involved in DECMA-1-induced apoptosis, yet whether the latter is p53-dependent needs further study.
To gain a better understanding of the putative mechanisms by which DECMA-1 administration suppressed the development of mammary carcinomas, we next examined whether DECMA-1 modulated the HER family of receptors. Importantly, the most intriguing and clinically relevant finding of this study is the demonstration that DECMA-1 co-localized with HER2 in MMTV-PyMT mAb-treated tumors and down-regulated many of the compensatory pathways that Trastuzumab-treated cells eventually develop so as to sustain cell proliferation and enhance survival. That is, one of the most important strategies to improve the efficacy of HER-targeted therapies is to inhibit multiple HER receptors, thereby interfering with the horizontal cooperatively that exists between these receptors Xia et al (2006) showed that the HER1/HER2 inhibitor, lapatinib, markedly reduced survivin expression and induced apoptosis through its inhibition of PI3K signaling in HER2 overexpressing BT474 cells (12) . Similarly, HER2-positive tumors from patients treated with lapatinib exhibited a marked inhibition of survivin expression levels (11, 12) . In contrast, Trastuzumab had little effect on Trastuzumab-resistant SUM190PT cell line, it induced the upregulation of both survivin and XIAP (12, 50) . In this study, we further show that DECMA-1 therapy down-regulated the inhibitor of apoptosis protein family members survivin, XIAP and c-IAP-1, many of which are essential for tumor cell survival and are also upregulated in Trastuzumab-resistant breast tumors (12) .
Because targeted monoclonal antibody based therapies, are not without untoward side effects and E-cadherin forms homotypic cell-cell adhesions in normal epithelial cells, we next evaluated DECMA-1 binding in human and mouse breast tumor specimens versus potential off-target binding in normal tissues. Importantly, Tsuiji et al (2007) demonstrated that the EC3-EC5 domains of E-cadherin are much less accessible to monoclonal antibody binding than EC1-EC2, and suggest that this masking may be due to the conformational state of cadherins or by other moieties (51) . In the current study, we show that DECMA-1 binds predominately to the ~80kDa ectodomain fragment in human breast tumor specimens and both intact E-cadherin and the 80kDa protein in mouse MMTV-PyMT tumors.
However, in non-reduced and reduced normal human skin tissue lysates (homogenized in PBS), DECMA-1 predominately bound the ectodomain fragment. This contrasted to the EC1 and EC2
antibodies, SHE78-7 and HECD-1, which bound both intact E-cadherin and the ectodomain fragment versus the cytosolic E-cadherin antibody which only bound the former. It would be tempting to speculate that the monomeric conformation of E-cadherin in tumor cells, versus the homodimeric conformation of E-cadherin in normal cells, may potentially unmask the epitopes necessary for this tumor-specific DECMA-1 binding. This lack of DECMA-1-induced cytotoxicity was further confirmed in an array of normal human cells. Moreover, in MMTV-PyMT mice there were no apparent signs of distress and histopathologic analysis of end-organs, including heart, liver, kidney and intestine showed no morphologic differences between treated mice and healthy controls. 
Disclosure of Potential Conflicts of Interest
The authors declare no competing financial or other interests. 
